Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Exenatide-PD3, reported in The Lancet in early 2025, was the largest and longest trial of a GLP-1R agonist in Parkinsons disease: 194 patients, once-weekly exenatide, 96 weeks
Gopal, P
There are plenty of alternatives without this complication
These actions combined help decrease the patients caloric intake and allow them to feel satiety after consuming smaller portion sizes
At a minimum, its Phase 3 entry (per our dataset) signals continued sponsor confidence that oral small-molecule GLP-1 can compete beyond a single companys platform
There are currently no clinical trials investigating the use of GLP-1RAs in patients with PTSD or OCD, leaving the clinical validation of these findings unexplored
US$ 28.99
US$ 26.34
US$ 20.20
US$ 27.23
US$ 27.00
